Farringdon Capital’s Intellia Therapeutics NTLA Stock Holding History

Farringdon Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,291	Closed	-$137K	–	525
2025 Q4	$137K	Buy	+15,291	New	+$210K	0.03%	402

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Farringdon Capital's NTLA Position: Q1 2026 in Review

Farringdon Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 15,291 shares — an estimated $137K sold.

Farringdon Capital first reported a position in NTLA in Q4 2025 and held it in 1 quarter. The position peaked at $137K in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Farringdon Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Farringdon Capital sold 15,291 Intellia Therapeutics shares in Q1 2026, an estimated $137K.
Farringdon Capital first reported a position in Intellia Therapeutics in Q4 2025 and held it in 1 quarter.
Farringdon Capital's Intellia Therapeutics position peaked at $137K in Q4 2025.
304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.